Valuation : VISEN Pharmaceuticals

Market Cap 1.87B 2.18B 278M 239M 223M 205M 385M 26.54B 386M 2.64B 1.03B 13.38B 1.04B 1.02B 44.27B P/E 2026 *
-18.2x
P/E 2027 * -30.6x
Enterprise Value 1.61B 1.87B 239M 205M 192M 176M 331M 22.82B 332M 2.27B 889M 11.5B 897M 878M 38.06B EV / Sales 2026 *
23.7x
EV / Sales 2027 * 4.18x
Free-Float
26.93%
Yield 2026 *
-
Yield 2027 * -
1 day-0.10%
1 week+1.52%
Current month+3.74%
1 month-0.10%
3 months-15.98%
6 months-39.05%
Current year-39.09%
1 week 19.81
Extreme 19.81
20
1 month 18.88
Extreme 18.88
20.28
Current year 18.5
Extreme 18.5
43.3
1 year 18.5
Extreme 18.5
47.1
3 years 18.5
Extreme 18.5
69.15
5 years 18.5
Extreme 18.5
69.15
10 years 18.5
Extreme 18.5
69.15
Manager TitleAgeSince
Chief Executive Officer 60 2018-11-06
Director of Finance/CFO 42 2025-10-12
Chief Tech/Sci/R&D Officer 54 2020-03-31
Director TitleAgeSince
Director/Board Member 60 2018-11-06
Director/Board Member 44 2021-01-07
Director/Board Member 60 2021-03-31
Date Insider Type Main position Quantity % Market Cap.
1/1/26 Other

Chief Executive Officer

108,750 0.0955%
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%+1.52%-56.16% - 278M
+0.10%+0.44%+2.80%+24.32% 50.96B
+2.65%+4.45%+481.36%+567.32% 46.18B
-0.88%+0.90%+24.11%+87.74% 42.73B
+0.33%+2.47%+38.97%+19.80% 43.04B
-2.27%-3.02%+14.22%+51.50% 33.48B
-1.21%-0.17%+29.16%+135.38% 17.28B
-0.36%-2.14% - - 16.43B
+0.25%+0.25%+12.03%+30.68% 14.73B
+0.44%+1.70%+82.07%+47.92% 14.09B
Average -0.10%+0.32%+69.84%+120.58% 27.92B
Weighted average by Cap. +0.04%+0.57%+104.18%+141.83%

Financials

2026 *2027 *
Net sales 67.73M 79M 10.08M 8.65M 8.1M 7.42M 13.97M 963M 14.01M 95.9M 37.49M 485M 37.84M 37.02M 1.61B 447M 522M 66.57M 57.14M 53.5M 48.99M 92.28M 6.36B 92.54M 633M 248M 3.2B 250M 245M 10.6B
Net income -99M -115M -14.73M -12.64M -11.84M -10.84M -20.42M -1.41B -20.48M -140M -54.8M -709M -55.3M -54.11M -2.35B -58M -67.65M -8.63M -7.41M -6.94M -6.35M -11.96M -824M -12M -82.12M -32.1M -415M -32.4M -31.7M -1.37B
Net Debt -262M -306M -39.03M -33.5M -31.36M -28.72M -54.1M -3.73B -54.26M -371M -145M -1.88B -147M -143M -6.22B 486K 567K 72.32K 62.08K 58.12K 53.22K 100K 6.91M 101K 688K 269K 3.48M 272K 266K 11.52M
Logo VISEN Pharmaceuticals
Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.
Employees
-
Date Price Change Volume
26-08-27 HK$19.98 -0.10% 7,600
26-08-26 HK$20.00 +0.10% 34,800
26-08-25 HK$19.98 0.00% 1,200
26-08-24 HK$19.98 0.00% 300
26-08-21 HK$19.98 +1.52% 12,200
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.13CNY
Average target price
44.50CNY
Spread / Average Target
+159.74%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2561 Stock